JP Morgan Chase’s Cogent Biosciences COGT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $10.3M | Sell |
258,952
-3,752
| -1% | -$131K | ﹤0.01% | 2771 |
|
|
2026
Q1 | $9.3M | Sell |
262,704
-138,227
| -34% | -$5.1M | ﹤0.01% | 2754 |
|
|
2025
Q4 | $14.2M | Buy |
400,931
+326,119
| +436% | +$9.17M | ﹤0.01% | 2372 |
|
|
2025
Q3 | $1.07M | Buy |
74,812
+5,533
| +8% | +$65.6K | ﹤0.01% | 4531 |
|
|
2025
Q2 | $497K | Sell |
69,279
-5,865
| -8% | -$32.5K | ﹤0.01% | 4789 |
|
|
2025
Q1 | $450K | Buy |
75,144
+13,684
| +22% | +$107K | ﹤0.01% | 4848 |
|
|
2024
Q4 | $479K | Sell |
61,460
-3,368
| -5% | -$33.6K | ﹤0.01% | 5063 |
|
|
2024
Q3 | $700K | Buy |
64,828
+5,720
| +10% | +$55.7K | ﹤0.01% | 4698 |
|
|
2024
Q2 | $498K | Sell |
59,108
-27,496
| -32% | -$209K | ﹤0.01% | 4691 |
|
|
2024
Q1 | $582K | Sell |
86,604
-36,590
| -30% | -$226K | ﹤0.01% | 4699 |
|
|
2023
Q4 | $724K | Sell |
123,194
-145,417
| -54% | -$1.11M | ﹤0.01% | 4548 |
|
|
2023
Q3 | $2.62M | Buy |
268,611
+1,953
| +0.7% | +$23.2K | ﹤0.01% | 3353 |
|
|
2023
Q2 | $3.16M | Sell |
266,658
-2,835
| -1% | -$32.5K | ﹤0.01% | 3212 |
|
|
2023
Q1 | $2.91M | Buy |
269,493
+28,073
| +12% | +$359K | ﹤0.01% | 3266 |
|
|
2022
Q4 | $2.79M | Buy |
241,420
+12,578
| +5% | +$156K | ﹤0.01% | 3306 |
|
|
2022
Q3 | $3.41M | Sell |
228,842
-127,066
| -36% | -$1.74M | ﹤0.01% | 3046 |
|
|
2022
Q2 | $3.21M | Buy |
355,908
+192,107
| +117% | +$1.31M | ﹤0.01% | 3162 |
|
|
2022
Q1 | $1.23M | Sell |
163,801
-52,644
| -24% | -$367K | ﹤0.01% | 4121 |
|
|
2021
Q4 | $1.86M | Buy |
216,445
+23,120
| +12% | +$201K | ﹤0.01% | 3919 |
|
|
2021
Q3 | $1.63M | Buy |
193,325
+24,104
| +14% | +$185K | ﹤0.01% | 3945 |
|
|
2021
Q2 | $1.37M | Sell |
169,221
-78,947
| -32% | -$667K | ﹤0.01% | 4071 |
|
|
2021
Q1 | $2.18M | Buy |
248,168
+180,954
| +269% | +$1.74M | ﹤0.01% | 3660 |
|
|
2020
Q4 | $755K | Buy |
+67,214
| New | +$739K | ﹤0.01% | 4126 |
|
|
2020
Q1 | – | Sell |
-60
| Closed | – | – | 5348 |
|
|
2019
Q4 | $0 | Buy |
+60
| New | +$245 | ﹤0.01% | 5629 |
|
|
2019
Q2 | – | Sell |
-1,161
| Closed | -$20K | – | 5785 |
|
|
2019
Q1 | $20K | Sell |
1,161
-8,416
| -88% | -$144K | ﹤0.01% | 5405 |
|
|
2018
Q4 | $168K | Buy |
9,577
+4,389
| +85% | +$130K | ﹤0.01% | 4658 |
|
|
2018
Q3 | $213K | Buy |
5,188
+5,008
| +2,782% | +$282K | ﹤0.01% | 4669 |
|
|
2018
Q2 | $10K | Buy |
+180
| New | +$8.65K | ﹤0.01% | 5369 |
|
Other funds holding COGT
JT
FFM
DM
TCM
JP Morgan Chase's COGT Position: Q2 2026 in Review
JP Morgan Chase reduced its Cogent Biosciences (COGT) stake by 1.4% in Q2 2026, selling an estimated $131K and leaving 258,952 shares worth $10.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2771.
JP Morgan Chase first reported a position in COGT in Q2 2018 and has held it in 28 quarters since. The position peaked at $14.2M in Q4 2025. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.
- JP Morgan Chase held 258,952 shares of Cogent Biosciences worth $10.3M as of Q2 2026.
- JP Morgan Chase sold 3,752 Cogent Biosciences shares in Q2 2026, an estimated $131K.
- Cogent Biosciences made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #2771 holding.
- JP Morgan Chase first reported a position in Cogent Biosciences in Q2 2018 and has held it in 28 quarters since.
- JP Morgan Chase's Cogent Biosciences position peaked at $14.2M in Q4 2025.
- 323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.